Analysis of Public Expenditure of Pharmaceutical Utilization of Female Infertility in Hungary in the Last Decade
Author(s)
Dalma Pónusz-Kovács, MSc1, Luca F. Kajos, MSc1, Tímea Csákvári, MSc, PhD2, Róbert Pónusz, MSc, PhD1, Diána Elmer, MSc, PhD1, Ákos Várnagy, MD, Ph.D., Habil3, József Bódis, MD, Ph.D., Habil3, Imre Boncz, MSc, PhD, MD1;
1University of Pécs, Faculty of Health Sciences, Institute for Health Insurance, Pécs, Hungary, 2University of Pécs, Faculty of Health Sciences, Institute for Health Insurance, Zalaegerszeg, Hungary, 3University of Pécs, National Laboratory on Human Reproduction, Pécs, Hungary
1University of Pécs, Faculty of Health Sciences, Institute for Health Insurance, Pécs, Hungary, 2University of Pécs, Faculty of Health Sciences, Institute for Health Insurance, Zalaegerszeg, Hungary, 3University of Pécs, National Laboratory on Human Reproduction, Pécs, Hungary
Presentation Documents
OBJECTIVES: In Hungary, the number of live births has been decreasing since multiple decades. The government has set a national strategic purpose to increase the accessibility to infertility treatments. The reform started in 2019, resulting in a significant increase in the state's involvement in providing and financing infertility treatments. This paper aims to evaluate the public expenditure related to infertility about pharmaceutical utilization in Hungary.
METHODS: During the research turnover data of prescriptions for infertility diagnoses was analyzed. The following WHO ICD (revision Xth.) infertility diagnoses were included in the study: N97.0; N97.1; N97.2; N97.3; N97.4; N97.8; N97.9. The study analyzed annual public expenditures linked to different infertility. Moreover, the market share linked to pharmaceutical products was also evaluated. The study database was provided by the Health Data Warehouse of the National Hospital General Directorate. The examined period covered 2015-2023 years. The cost was set in USD (the mean value of 1 USD during the study period= 301.70 HUF).
RESULTS: The total public expenditure for infertility-related pharmaceutical utilization was 104.52 million USD in Hungary. The highest level was identified in 2023 (19.46 million USD) while the lowest was in 2015 (5.95 million USD). A significant difference was captured in expenditure linked to diagnosis. The highest market share was represented by N97.9 ICD (female infertility, unspecified; 87.76 million USD). Expenditure by active substance represented a different outcome. The highest expenditure was related to follitropin alfa (48.17 million USD), progesteron (8.80 million USD) and alfa follitropin/ alfa lutropin (8.43 million USD).
CONCLUSIONS: The public expenditure has increasing remarkably during the study period. From the year of the reform, the government took on a greater role by increasing public subsidies for infertility-related pharmaceuticals. Based on the result, the financial burden of Hungarian patients related to infertility treatment has been relieved.
METHODS: During the research turnover data of prescriptions for infertility diagnoses was analyzed. The following WHO ICD (revision Xth.) infertility diagnoses were included in the study: N97.0; N97.1; N97.2; N97.3; N97.4; N97.8; N97.9. The study analyzed annual public expenditures linked to different infertility. Moreover, the market share linked to pharmaceutical products was also evaluated. The study database was provided by the Health Data Warehouse of the National Hospital General Directorate. The examined period covered 2015-2023 years. The cost was set in USD (the mean value of 1 USD during the study period= 301.70 HUF).
RESULTS: The total public expenditure for infertility-related pharmaceutical utilization was 104.52 million USD in Hungary. The highest level was identified in 2023 (19.46 million USD) while the lowest was in 2015 (5.95 million USD). A significant difference was captured in expenditure linked to diagnosis. The highest market share was represented by N97.9 ICD (female infertility, unspecified; 87.76 million USD). Expenditure by active substance represented a different outcome. The highest expenditure was related to follitropin alfa (48.17 million USD), progesteron (8.80 million USD) and alfa follitropin/ alfa lutropin (8.43 million USD).
CONCLUSIONS: The public expenditure has increasing remarkably during the study period. From the year of the reform, the government took on a greater role by increasing public subsidies for infertility-related pharmaceuticals. Based on the result, the financial burden of Hungarian patients related to infertility treatment has been relieved.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
HPR74
Topic
Health Policy & Regulatory
Topic Subcategory
Insurance Systems & National Health Care, Public Spending & National Health Expenditures
Disease
SDC: Reproductive & Sexual Health